Lancaster Kathryn E, Stockton Melissa, Remch Molly, Wester C William, Nash Denis, Brazier Ellen, Adedimeji Adebola, Finlayson Robert, Freeman Aimee, Hogan Breanna, Kasozi Charles, Kwobah Edith Kamaru, Kulzer Jayne Lewis, Merati Tuti, Tine Judiacel, Poda Armel, Succi Regina, Twizere Christelle, Tlali Mpho, Groote Per von, Edelman E Jennifer, Parcesepe Angela M
Wake Forest University School of Medicine, Winston-Salem, NC, USA.
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Int J Drug Policy. 2024 Feb;124:104309. doi: 10.1016/j.drugpo.2023.104309. Epub 2024 Jan 15.
Overwhelming evidence highlights the negative impact of substance use on HIV care and treatment outcomes. Yet, the extent to which alcohol use disorder (AUD) and other substance use disorders (SUD) services have been integrated within HIV clinical settings is limited. We describe AUD/SUD screening and treatment availability in HIV clinical sites participating in the International epidemiology Databases to Evaluate AIDS (IeDEA) consortium.
In 2020, 223 IeDEA HIV clinical sites from 41 countries across seven geographic regions completed a survey on capacity and practices related to management of AUD/ SUD. Sites provided information on AUD and other SUD screening and treatment practices.
Sites were from low-income countries (23%), lower-middle-income countries (38%), upper-middle income countries (17%) and high-income counties (23%). AUD and SUD screening using validated instruments were reported at 32% (n=71 located in 12 countries) and 12% (n=27 located in 6 countries) of the 223 sites from 41 countries, respectively. The North American region had the highest proportion of clinics that reported AUD screening (76%), followed by East Africa (46%); none of the sites in West or Central Africa reported AUD screening. 31% (n=69) reported both AUD screening and counseling, brief intervention, psychotherapy, or Screening, Brief Intervention, and Referral to Treatment; 8% (n=18) reported AUD screening and detox hospitalization; and 10% (n=24) reported both AUD screening and medication. While the proportion of clinics providing treatment for SUD was lower than those treating AUD, the prevalence estimates of treatment availability were similar.
Availability of screening and treatment for AUD/SUD in HIV care settings is limited, leaving a substantial gap for integration into ongoing HIV care. A critical understanding is needed of the multilevel implementation factors or feasible implementation strategies for integrating screening and treatment of AUD/SUD into HIV care settings, particularly for resource-constrained regions.
大量证据凸显了物质使用对艾滋病病毒(HIV)护理及治疗结果的负面影响。然而,酒精使用障碍(AUD)及其他物质使用障碍(SUD)服务在HIV临床环境中的整合程度有限。我们描述了参与国际评估艾滋病流行病学数据库(IeDEA)联盟的HIV临床场所中AUD/SUD筛查及治疗的可及性。
2020年,来自七个地理区域41个国家的223个IeDEA HIV临床场所完成了一项关于AUD/SUD管理能力及实践的调查。各场所提供了有关AUD及其他SUD筛查和治疗实践的信息。
这些场所来自低收入国家(23%)、中低收入国家(38%)、中高收入国家(17%)和高收入国家(23%)。在来自41个国家的223个场所中,分别有32%(n = 71,位于12个国家)和12%(n = 27,位于6个国家)的场所报告使用经过验证的工具进行AUD和SUD筛查。北美地区报告进行AUD筛查的诊所比例最高(76%),其次是东非(46%);西非或中非没有场所报告进行AUD筛查。31%(n = 69)的场所报告同时进行AUD筛查及咨询、简短干预、心理治疗或筛查、简短干预及转介治疗;8%(n = 18)的场所报告进行AUD筛查及戒毒住院治疗;10%(n = 24)的场所报告同时进行AUD筛查及药物治疗。虽然提供SUD治疗的诊所比例低于治疗AUD的诊所,但治疗可及性的患病率估计相似。
HIV护理环境中AUD/SUD筛查及治疗的可及性有限,在将其整合到正在进行的HIV护理中存在很大差距。需要深入了解将AUD/SUD筛查及治疗整合到HIV护理环境中的多层次实施因素或可行的实施策略,特别是对于资源有限的地区。